HealthTab™ and HeartEye Open New Referral Pathway into Community Pharmacy

Avricore Health’s wholly owned subsidiary HealthTab completed an integration with UK-based HeartEye, linking AI retinal scans that identify elevated cardiovascular risk to referrals for further assessment and care at nearby HealthTab-enabled pharmacies. HealthTab and Abbott plan to showcase the point-of-care testing solution, including the integration, at The Pharmacy Show in Birmingham on October 11–12, 2026.

Analysis

The strategic value is a potential patient-acquisition funnel, not the AI feature itself: optician screening could direct higher-risk patients into pharmacy-based testing, but only if referrals convert into completed assessments and repeatable pharmacy workflows. The key unknowns are deployment count, referral volume, conversion rate, reimbursement or payer support, and revenue attribution between HealthTab and its partners. Without those, this is not evidence of a material earnings contribution.

For AVCR, the Oct. 11–12 showcase is a near-term visibility catalyst, but any price response could outrun proof of adoption. Over 1–3 months, look for signed deployments and quantified utilization; over 6–18 months, the thesis depends on scaling across pharmacy networks and demonstrating sustainable unit economics. A weak funnel could instead expose integration and support costs without meaningful recurring revenue. UK pharmacy and optical operators may benefit if the pathway improves patient engagement, while competing screening and pharmacy-testing platforms face pressure to match connected referral workflows.

ABT’s participation does not establish incremental product sales, exclusivity, or a material contribution to consolidated results. Treat it as ecosystem validation, not an ABT earnings catalyst. The contrarian risk is that investors capitalize a partnership announcement before commercial traction is independently visible; the upside case is that low-cost distribution through existing community settings makes adoption faster than a standalone clinic-sales model.

Key Decisions for Investors

• AVCR: Prefer a watchlist/alert over chasing the announcement. Reassess on disclosed pharmacy deployments, referral-to-test conversion, recurring revenue, and gross-margin contribution; avoid treating event attendance as proof of demand.
• AVCR falsification: downgrade the adoption thesis if follow-up disclosures show no expansion beyond the initial integration, low utilization, or no identifiable commercial model over the next 1–3 months. Verify whether any announced activity is paid and who bears implementation costs.
• ABT: No standalone trade on this item. Seek evidence of product orders, a commercial agreement, or a quantified contribution before assigning earnings value; the current information supports strategic association only.
• Monitor UK pharmacy and optical-channel adoption over 6–18 months. Faster rollout with repeatable economics would strengthen the platform case; reimbursement friction, poor referral conversion, or competing workflows gaining distribution would weaken it.